ASCO: Elinzanetant Cuts Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy
By Elana Gotkine HealthDay Reporter
TUESDAY, June 3, 2025 -- For women with moderate-to-severe vasomotor symptoms associated with endocrine therapy for hormone receptor (HR)-positive breast cancer, elinzanetant, a neurokinin-targeted therapy, reduces the frequency of vasomotor symptoms, according to a study published online June 2 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.
Fatima Cardoso, M.D., from the Champalimaud Foundation in Lisbon, Portugal, and colleagues performed a phase 3 trial involving women aged 18 to 70 years with moderate-to-severe vasomotor symptoms associated with endocrine therapy for HR-positive breast cancer or its prevention. Women were randomly assigned to receive once-daily elinzanetant at a dose of 120 mg for 52 weeks or once-daily placebo for 12 weeks followed by once-daily elinzanetant at a dose of 120 mg for 40 weeks (316 and 158 patients, respectively). Only one of the patients was taking endocrine therapy for breast cancer prevention.
The researchers found that the mean change from baseline in the mean daily frequency of moderate-to-severe vasomotor symptoms at week 4 was −6.5 and −3.0 episodes for those receiving elinzanetant and placebo, respectively (least-squares mean difference, −3.5 episodes). The mean change was −7.8 and −4.2 episodes among those receiving elinzanetant and placebo, respectively, at week 12 (least-squares mean difference, −3.4 episodes). Overall, 69.8 and 62.0 percent of those receiving elinzanetant and placebo, respectively, reported at least one adverse event during weeks 1 through 12; serious adverse events occurred in 2.5 and 0.6 percent, respectively.
"In a finding consistent with the results of previous trials involving postmenopausal women, treatment with elinzanetant resulted in significant decreases in the frequency of vasomotor symptoms and in sleep disturbances and improvements in health-related quality of life among women with moderate-to-severe vasomotor symptoms taking endocrine therapy for breast cancer," the authors write.
Several authors disclosed ties to Bayer, which is developing elinzanetant and funded the study.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
ENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy Use
TUESDAY, July 15, 2025 -- In postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is associated with superior weight loss...
Many Indicators of Anger Expression Decrease With Age in Women
THURSDAY, July 10, 2025 -- Aging is significantly related to anger in women, with most indicators of anger expression decreasing with age, according to a study published online...
Stratifying BMI by Waist Circumference Improves Mortality Risk Prediction in Postmenopausal Women
THURSDAY, July 10, 2025 -- Stratifying body mass index (BMI) categories by waist circumference (WC) thresholds improves mortality risk prediction in postmenopausal women...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.